Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IO

- PMLiVE

Tecentriq combo gains European NSCLC approval

Triple combination approved after targeted therapy

- PMLiVE

Immuno-oncology in 2019: the rapid evolution continues

Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?

- PMLiVE

Immunotherapy combination trials Q&A

By Chris Learn and Martin Lachs

- PMLiVE

Neoantigen player Achilles gets OK for first clinical trial

Will test the candidate in advanced NSCLC patients

- PMLiVE

Nektar confirms BMS deal for NKTR-214 is on track

Shares in Nektar rose 10% in the wake of the presentation at JPM healthcare conference

- PMLiVE

AZ still sees route to approval for Imfinzi in MYSTIC trial

New analysis shows opportunity in NSCLC

- PMLiVE

AZ’s MYSTIC survival data is in – and it’s a bust

Imfinzi failed to achieve OS improvement

- PMLiVE

Pfizer claims rapid FDA nod for Lorbrena

Green light is latest in a string of cancer drug approvals

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

- PMLiVE

AstraZeneca: building a new ‘open innovation’ pharma company

The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects

- PMLiVE

FDA approval gained, Pfizer sets sights on first-line NSCLC market

Vizimpro could challenge Tagrisso, survival data will be key

- PMLiVE

Imfinzi aces survival challenge in lung cancer

Earlier treatment leads to much extended lives, data suggests

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links